Identifies Chemical Adulteration of Food Through Advanced Gas Chromatography/Mass Spectrometry Technology
WALTHAM, Mass. – PerkinElmer, Inc. (NYSE: PKI), a global leader in Health
Sciences and Photonics markets, today announced a complete analytical solution for the
determination of melamine adulteration in protein-based foods. With the release of the
Melamine Analyzer, based on the innovative Clarus® 600 T Gas Chromatograph/Mass
Spectrometer (GC/MS), PerkinElmer is the first in the industry to provide such solution
using GC/MS technology.
“PerkinElmer is putting significant effort behind developing solutions focused on the
analysis, determination and monitoring of product safety and agricultural, food
production and processing environments to test various aspects of safety and quality,”
said Dr. Richard Begley, President, PerkinElmer Analytical Sciences. PerkinElmer’s
Melamine Analyzer is the first in an anticipated new series of complete application
solutions designed to help laboratories analyze food safety and quality.
“This analyzer is designed to provide laboratories a complete application solution
including the technology, applications support, software and expertise that will enable
them to quickly and easily begin analyzing for melamine, thereby reducing the future risk
of melamine-contaminated product entering the market,” Begley added.
Begley noted that as part of PerkinElmer’s increased focus on food safety and quality,
PerkinElmer provided testimony during the Interagency Working Group on Import Safety
in Washington, D.C. on October 1, 2007. With deep expertise in global analytical testing
needs and requirements in food analysis, PerkinElmer’s testimony included
recommendations and opinions about the analytical measurement instrumentation,
methods, support and education necessary to help ensure safety in food imports.
The Melamine Analyzer includes all instrumentation, consumables and applications
resources needed to screen for melamine contamination, conforming with the most recent
guideline from the U.S. Food and Drug Administration (FDA).
The method for the Melamine Analyzer was developed in collaboration with Flora
Research Laboratories, a Food and Drug Administration and U.S. Drug Enforcement
Agency-registered independent testing laboratory specializing in natural products.
Melamine is a nitrogen-rich industrial chemical that became well-known in North
America recently after its presence in wheat gluten was linked with renal failure in dogs
and cats.1 The FDA quickly issued a standard test method for the analysis of melamine
in protein materials using GC/MS.
PerkinElmer instrumentation is used in food safety and quality assurance, encompassing
research and testing areas – such as authenticity, potency, manufacturing and
contamination – that are directly relevant to the health of all living things. PerkinElmer’s
Melamine Analyzer can help test the safety of the food supply from the source of
ingredients to the final product with a high level of sensitivity and reliability.
For more information on the PerkinElmer Melamine Analyzer, visit
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including, but not limited to, statements
relating to estimates and projections of future earnings per share, cash flow and revenue
growth and other financial results, developments relating to our customers and endmarkets,
and plans concerning business development opportunities. Words such as
“believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will”
and similar expressions, and references to guidance, are intended to identify forwardlooking
statements. Such statements are based on management’s current assumptions
and expectations and no assurances can be given that our assumptions or expectations
will prove to be correct. A number of important risk factors could cause actual results to
differ materially from the results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) our failure to introduce new
products in a timely manner; (2) our ability to execute acquisitions and license
technologies, or to successfully integrate acquired businesses and licensed technologies
into our existing business or to make them profitable; (3) our failure to protect adequately
our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our
ability to compete effectively; (6) fluctuation in our quarterly operating results and our
ability to adjust our operations to address unexpected changes; (7) our ability to produce
an adequate quantity of products to meet our customers’ demands; (8) our failure to
maintain compliance with applicable government regulations; (9) regulatory changes;
(10) economic, political and other risks associated with foreign operations; (11) our
ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to
realize the full value of our intangible assets; and (14) other factors which we describe
under the caption “Risk Factors” in our most recent annual report on Form 10-K and in
our most recent quarterly report on Form 10-Q and in our other filings with the Securities
and Exchange Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after the date of this
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health
Sciences and Photonics markets to improve the quality of life. The Company reported
revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than
125 countries, and is a component of the S&P 500 Index. Additional information is
available through www.perkinelmer.com or 1-877-PKI-NYSE.
# # #